of 3.6 ml/s followed by 35 ml of contrast agent and 30 ml of saline solution, each at a flow rate of 1.8 ml/s, with a dual injector. The region of interest was placed within the ascending aorta, and the scan was started when the computed tomography (CT) density reached 100 Hounsfield units higher than the baseline CT density. The scan was performed between the tracheal bifurcation and diaphragm with the following parameters: collimation width 0.5 mm, rotation speed 0.4 s/rotation, tube voltage 135 kV, effective tube current 360 mA.
Any narrowing of the normal contrast-enhanced lumen to <50% that could be identified in multiplanar reconstructions or cross-sectional images was defined as a significantly stenosed vessel (VD) in CAD. Subjects were classified into 4 groups according to the number of significantly stenosed coronary vessels (0-3 VD).
Cardiovascular Risk Factors
In all subjects, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), serum levels of triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), uric acid (UA), fasting plasma glucose, hemoglobin A1c (HbA1c), smoking status (current vs nonsmokers), family history (myocardial infarction, angina pectoris or sudden death) and medication use were recorded as cardiovascular risk factors. Blood pressure (BP) was determined as the mean of 2 measurements obtained in an office setting by the conventional cuff method using a mercury sphygmomanometer after at least 5 min of rest.
All blood samples were drawn in the morning after the patients had fasted overnight. Concentrations of TC, TG, HDL-C, LDL-C and UA were measured by enzymatic methods on an autoanalyzer (Hitachi 7600-020S; Hitachi High-Technologies, Tokyo, Japan) using reagent kits from Daiichi Pure Chemicals (Tokyo, Japan). LDL-C was measured directly using a kit without a formula for LDL-C. Concentrations of fasting plasma glucose were determined using the glucose oxidase-oxygen electrode method. HbA1c, excluding unstable fractions, was determined by high-pressure liquid chromatography. Plasma levels of adiponectin were determined with an adiponectin ELISA kit. 13 The patients' characteristics were obtained from medical records with regard to history of HT, HL, DM, history of smoking, previous myocardial infarction, and prior coronary intervention. Patients who were considered to have HT had a current SBP/DBP ≥140/90 mmHg or were receiving antihypertensive therapy. Patients with hypercholesterolemia were defined as those with LDL-C ≥140 mg/dl and/or TG ≥150 mg/dl or who were receiving lipid-lowering therapy. DM was defined using the American Diabetes Association criteria. BMI was calculated as weight (kg)/height (m) 2 . 
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Hyperuricemia was defined as serum UA level ≥7.0 mg/dl or the administration of UA-lowering drugs. For the measurement of visceral fat area (VFA), subcutaneous fat area (SFA) and waist circumference (WC), all subjects underwent CT scanning in the routine supine position. The measurements were made on CT cross-sectional scans at the level of the umbilicus using specific software (Fat Scan, N2 System, Hyogo, Japan).
Diagnostic Criteria for MetS
MetS was diagnosed by the criteria published by the Examination Committee of Criteria for Diagnosis of Metabolic Syndrome in Japan in 2005: VFA ≥100 cm 2 and the presence of more than 2 of the following: HT (SBP ≥130 mmHg or DBP ≥85 mmHg or taking an anti-hypertensive drug) or HL (TG ≥150 mg/dl or 40 mg/dl ≥ HDL-C or taking lipid-lowering drugs) or high fasting glucose (fasting glucose ≥110 mg/dl or taking glucose-lowering drugs). 14 Subjects were classified according to the number of these components of MetS.
Statistical Analysis
Statistical analysis was performed using the StatView statistical software package (StatView 5; SAS Institute Inc, Cary, NC, USA) at Fukuoka University. Data are shown as the mean ± standard deviation. Categorical and continuous variables were compared between groups by chi-square analysis and analysis of variance followed by Fisher's protected least significant difference, respectively. A value of P<0.05 was considered significant. Multivariate analysis was performed by logistic regression analysis for independent variables that were related to the VD groups. Table 1 shows the baseline clinical characteristics of the 313 patients, comprising 158 (50.5%) men and 155 (49.5%) When the subjects were divided into non-MetS and MetS groups, VD in the MetS group tended to be higher than that in the non-MetS group among the parameters related to MDCT, but not significantly.
Results

Patient Characteristics
Correlation Between Plasma Levels of Adiponectin and Clinical Parameters
As shown in Table 2 , plasma levels of adiponectin were negatively correlated with BMI, DBP, TG, HbA1c, fasting glucose, SFA, VFA and WC, and positively correlated with age and HDL-C. Furthermore, plasma levels of adiponectin in men, current smokers, HL, DM and MetS were significantly lower than those in women, non-smokers, non-HL, non-DM and non-MetS, respectively.
Correlation Between the Number of Metabolic Factors and Patient Characteristics
When the subjects were divided into 5 groups (0-4) according to the number of metabolic factors (VFA ≥100 cm 2 , fasting glucose ≥110 mg/dl, SBP ≥135 and/or DBP ≥85 mmHg, TG ≥150 and/or HDL-C <40 mg/dl), plasma adiponectin levels significantly decreased (Fig 1A) , and VD using MDCT significantly increased as the number increased (Fig 1B) . In addition, subjects were divided into quartile groups according to HDL-C: <43 mg/dl, 43-51 mg/dl, 51-62 mg/dl and ≥62 mg/dl. The number of VD significantly increased with a decrease in the HDL-C level. The number of VD in the 1 st quartile was significantly higher than in the 3 rd and 4 th quartiles, and that in the 2 nd quartile was significantly higher than that in the 4 th quartile (Fig 2) .
Comparison of Parameters With Regard to the Number of VD
Next, the number of VD by MDCT was significantly associated with HT, hyperuricemia, SBP, HDL-C, LDL-C, medication with angiotensin II receptor blocker and calciumchannel blocker (Table 3) . Multivariate logistic regression analysis revealed that the number of VD was most closely correlated with HDL-C (P=0.0014).
Discussion
In the present study, we demonstrated that lower levels of HDL-C were most strongly correlated to the number of VD. Our results indicate that lower levels of HDL-C may Association between the number of metabolic factors and the number of stenosed vessels (VD) in coronary artery disease (A) and plasma levels of adiponectin (B). Metabolic factors: visceral fat area ≥100 cm 2 , fasting glucose ≥110 mg/dl, systolic blood pressure ≥135 mmHg and/or diastolic blood pressure ≥85 mmHg, triglyceride ≥150 and/or high-density lipoprotein-cholesterol <40 mg/dl. *P<0.05, **P<0.01, ***P<0.0001. predict the severity of CAD independent of other metabolic markers such as adiponectin, VFA or present medication in patients with suspected CAD when MDCT is performed as a non-invasive method for screening. MetS, which represents a cluster of insulin resistance, glucose intolerance, HT and HL, is a common basis for the development of atherogenic cardiovascular diseases, especially CAD, in industrial countries exposed to overnutrition. 15 Although the molecular basis of MetS has not been elucidated, adiponectin is an adipose-derived protein with multivalent functions including anti-atherogenic, insulinsensitizing, lipid-oxidation enhancing, and vasodilatory activities. [16] [17] [18] [19] Therefore, it is possible that decreased plasma levels of adiponectin may play a significant role in the development of MetS. In the present study, we showed that decreased plasma levels of adiponectin were significantly correlated with the number of metabolic factors, so the plasma level of adiponectin may be a useful biomarker for MetS.
In the present cross-sectional study, plasma levels of adiponectin were negatively correlated with BMI, DBP, TG, HbA1c, fasting glucose, SFA, VFA and WC, and positively correlated with age and HDL-C. Similar results have been reported previously. 13 Recent longitudinal studies have also shown that plasma levels of adiponectin in patients with end-stage renal disease predict new cardiovascular events, 20 and patients in the lower adiponectin tertile had a 1.56-fold increase in the relative risk of adverse cardiovascular events compared with those in the higher tertile. However, in the present study there was no association between plasma levels of adiponectin and the VD ( Table 3) . Nakamura et al demonstrated that plasma levels of adiponectin were significantly lower in patients with unstable angina than in those with stable angina, but there was no difference between patients with stable angina and those without CAD in the plasma levels of adiponectin. 6 Because subjects with CAD, as evaluated by MDCT, were diagnosed in the present study as having stable angina based on their symptoms, no difference was seen between subjects with and without CAD for plasma levels of adiponectin.
HDL-C is a lipoprotein with a particularly complex connection to MetS. Epidemiological studies have established that low plasma levels of HDL-C are a major risk factor for CAD, [21] [22] [23] even after adjusting for other risk factors. 23 An analysis of 4 large epidemiological studies revealed that an increase in the HDL-C level of 1 mg/dl was associated with a decrease in CAD risk of 2-3%. 21 Thus, HDL-C was a CAD risk factor of approximately equal magnitude to LDL-C in those studies. In addition, HDL-C levels were more recently shown to predict major cardiovascular events in patients with LDL-C levels below 70 mg/dl after statin treatment. 24 The present study showed that the number of VD determined by MDCT was most closely correlated with HDL-C levels, independent of other metabolic markers such as adiponectin ( Table 3) . Previous longitudinal epidemiological studies have demonstrated an inverse association between HDL-C level and the prevalence of CAD or mortality, 25, 26 and the Japan Lipid Intervention Trial (J-LIT), a large cohort study in Japan, also revealed that the HDL-C level was inversely related to the risk of coronary events. 27 In the J-LIT study, the incidence of coronary events was lower in patients with HDL-C level ≥50 mg/dl and higher in those with HDL-C <40 mg/dl compared with patients whose HDL-C level was between 40 and 49 mg/dl. The present study could not evaluate the incidence of CAD because of its cross-sectional design; however, our results using MDCT revealed a similar trend: an inverse relationship between quartiles of HDL-C and the severity of CAD (Fig 2) . The relationship between non-alcoholic fatty liver disease (NAFLD) and MetS is being increasingly recognized. Approximately 90% of patients with NAFLD have at least 1 component of MetS and 33% have the complete diagnosis. 28 Furthermore, the presence of MetS predicts a higher risk for the development of NAFLD in both men and women. 29 In the present study, however, this relationship was not examined because of a lack of data regarding liver function.
Study Limitations
This study has 3 important limitations. First, although MDCT is not the gold standard for the evaluation of coronary stenosis, recent studies have shown that both its sensitivity and specificity compared with invasive CAG for the identification of significant coronary stenosis are approximately 95%. 30, 31 Second, coronary stenosis with severe coronary calcification was not evaluated. Thus, the true number of VD in segments with severe calcification should be higher. Third, we examined the relationship between the parameters and MetS as defined by both Japanese and IDF criteria (data not shown). A major difference in the comparison of the Japanese and IDF criteria is that the percentage of males with MetS was higher than that of females under the Japanese criteria, whereas the opposite relationship was found under the IDF criteria. This difference between the Japanese and IDF criteria may reflect some serious problems. However, that was not under investigation in this study, and other significant differences between the non-MetS and MetS groups as defined by IDF criteria were similar to those under the Japanese criteria.
In conclusion, we diagnosed CAD using a non-invasive method, MDCT, and analyzed its association with MetS using an accurate method. Based on the results of this cross-sectional study, lower levels of HDL-C may be the most useful for predicting CAD independent of other metabolic markers such as lower levels of adiponectin, VFA or present medication.
